TY - JOUR AU - Mahoney, K. M. AU - Rennert, P. D. AU - Freeman, G. J. PY - 2015 DA - 2015// TI - Combination cancer immunotherapy and new immunomodulatory targets JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4591 DO - 10.1038/nrd4591 ID - Mahoney2015 ER - TY - JOUR AU - Kuehn, B. M. PY - 2017 DA - 2017// TI - The promise and challenges of CAR-T gene therapy JO - JAMA VL - 318 UR - https://doi.org/10.1001/jama.2017.15605 DO - 10.1001/jama.2017.15605 ID - Kuehn2017 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Ansell, S. M. AU - Lesokhin, A. M. AU - Borrello, I. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - June, C. H. AU - Sadelain, M. PY - 2018 DA - 2018// TI - Chimeric antigen receptor therapy JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMra1706169 DO - 10.1056/NEJMra1706169 ID - June2018 ER - TY - JOUR AU - Schadendorf, D. AU - Hodi, F. S. AU - Robert, C. PY - 2015 DA - 2015// TI - Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2736 DO - 10.1200/JCO.2014.56.2736 ID - Schadendorf2015 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Park, J. H. AU - Riviere, I. AU - Gonen, M. PY - 2018 DA - 2018// TI - Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709919 DO - 10.1056/NEJMoa1709919 ID - Park2018 ER - TY - JOUR AU - Abid, M. B. PY - 2019 DA - 2019// TI - Could the menagerie of the gut microbiome really cure cancer? Hope or hype JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0561-9 DO - 10.1186/s40425-019-0561-9 ID - Abid2019 ER - TY - JOUR AU - Yi, M. AU - Yu, S. AU - Qin, S. PY - 2018 DA - 2018// TI - Gut microbiome modulates efficacy of immune checkpoint inhibitors JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0592-6 DO - 10.1186/s13045-018-0592-6 ID - Yi2018 ER - TY - JOUR AU - Selby, M. J. AU - Engelhardt, J. J. AU - Quigley, M. PY - 2013 DA - 2013// TI - Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0013 DO - 10.1158/2326-6066.CIR-13-0013 ID - Selby2013 ER - TY - JOUR AU - Carbonnel, F. AU - Soularue, E. AU - Coutzac, C. PY - 2017 DA - 2017// TI - Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? JO - Semin Immunopathol VL - 39 UR - https://doi.org/10.1007/s00281-016-0613-x DO - 10.1007/s00281-016-0613-x ID - Carbonnel2017 ER - TY - JOUR AU - Romano, E. AU - Kusio-Kobialka, M. AU - Foukas, P. G. PY - 2015 DA - 2015// TI - Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients JO - Proc Natl Acad Sci USA VL - 112 UR - https://doi.org/10.1073/pnas.1417320112 DO - 10.1073/pnas.1417320112 ID - Romano2015 ER - TY - JOUR AU - Tarhini, A. A. AU - Zahoor, H. AU - Lin, Y. PY - 2015 DA - 2015// TI - Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-015-0081-1 DO - 10.1186/s40425-015-0081-1 ID - Tarhini2015 ER - TY - JOUR AU - Callahan, M. K. AU - Yang, A. AU - Tandon, S. PY - 2011 DA - 2011// TI - Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.2505 DO - 10.1200/jco.2011.29.15_suppl.2505 ID - Callahan2011 ER - TY - JOUR AU - Li, S. AU - Zhang, J. AU - Wang, M. PY - 2018 DA - 2018// TI - Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB JO - Br J Haematol VL - 181 UR - https://doi.org/10.1111/bjh.15195 DO - 10.1111/bjh.15195 ID - Li2018 ER - TY - JOUR AU - Abid, M. B. PY - 2018 DA - 2018// TI - The revving up of CARs JO - Gene Ther VL - 25 UR - https://doi.org/10.1038/s41434-018-0015-x DO - 10.1038/s41434-018-0015-x ID - Abid2018 ER - TY - JOUR AU - Maude, S. L. AU - Laetsch, T. W. AU - Buechner, J. PY - 2018 DA - 2018// TI - Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1709866 DO - 10.1056/NEJMoa1709866 ID - Maude2018 ER - TY - JOUR AU - Neelapu, S. S. AU - Locke, F. L. AU - Bartlett, N. L. PY - 2017 DA - 2017// TI - Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1707447 DO - 10.1056/NEJMoa1707447 ID - Neelapu2017 ER - TY - JOUR AU - Viaud, S. AU - Saccheri, F. AU - Mignot, G. PY - 2013 DA - 2013// TI - The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide JO - Science VL - 342 UR - https://doi.org/10.1126/science.1240537 DO - 10.1126/science.1240537 ID - Viaud2013 ER - TY - JOUR AU - Paulos, C. M. AU - Wrzesinski, C. AU - Kaiser, A. PY - 2007 DA - 2007// TI - Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling JO - J Clin Invest VL - 117 UR - https://doi.org/10.1172/JCI32205 DO - 10.1172/JCI32205 ID - Paulos2007 ER - TY - JOUR AU - Xu, X. AU - Zhang, X. PY - 2015 DA - 2015// TI - Effects of cyclophosphamide on immune system and gut microbiota in mice JO - Microbiol Res VL - 171 UR - https://doi.org/10.1016/j.micres.2014.11.002 DO - 10.1016/j.micres.2014.11.002 ID - Xu2015 ER - TY - JOUR AU - Uribe-Herranz, M. AU - Bittinger, K. AU - Rafail, S. PY - 2018 DA - 2018// TI - Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12 JO - JCI Insight VL - 3 UR - https://doi.org/10.1172/jci.insight.94952 DO - 10.1172/jci.insight.94952 ID - Uribe-Herranz2018 ER - TY - JOUR AU - Routy, B. AU - Gopalakrishnan, V. AU - Daillere, R. AU - Zitvogel, L. AU - Wargo, J. A. AU - Kroemer, G. PY - 2018 DA - 2018// TI - The gut microbiota influences anticancer immunosurveillance and general health JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/s41571-018-0006-2 DO - 10.1038/s41571-018-0006-2 ID - Routy2018 ER - TY - JOUR AU - Routy, B. AU - Chatelier, E. AU - Derosa, L. PY - 2018 DA - 2018// TI - Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan3706 DO - 10.1126/science.aan3706 ID - Routy2018 ER - TY - JOUR AU - Vetizou, M. AU - Pitt, J. M. AU - Daillere, R. PY - 2015 DA - 2015// TI - Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad1329 DO - 10.1126/science.aad1329 ID - Vetizou2015 ER - TY - JOUR AU - Kuczma, M. P. AU - Ding, Z. C. AU - Li, T. PY - 2017 DA - 2017// TI - The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.22953 DO - 10.18632/oncotarget.22953 ID - Kuczma2017 ER - TY - JOUR AU - Akalin, I. P. S. AU - Angelis, B. D. PY - 2009 DA - 2009// TI - Effects of chimeric antigen receptor (CAR) expression on regulatory T cells JO - Mol Ther VL - 17 ID - Akalin2009 ER - TY - JOUR AU - Duell, J. AU - Dittrich, M. AU - Bedke, T. PY - 2017 DA - 2017// TI - Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2017.41 DO - 10.1038/leu.2017.41 ID - Duell2017 ER - TY - JOUR AU - Fraietta, J. A. AU - Lacey, S. F. AU - Orlando, E. J. PY - 2018 DA - 2018// TI - Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0010-1 DO - 10.1038/s41591-018-0010-1 ID - Fraietta2018 ER - TY - JOUR AU - Omenetti, S. AU - Pizarro, T. T. PY - 2015 DA - 2015// TI - The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome JO - Front Immunol VL - 6 UR - https://doi.org/10.3389/fimmu.2015.00639 DO - 10.3389/fimmu.2015.00639 ID - Omenetti2015 ER - TY - JOUR AU - Vignali, D. A. AU - Collison, L. W. AU - Workman, C. J. PY - 2008 DA - 2008// TI - How regulatory T cells work JO - Nat Rev Immunol VL - 8 UR - https://doi.org/10.1038/nri2343 DO - 10.1038/nri2343 ID - Vignali2008 ER - TY - JOUR AU - Ruella, M. AU - Maus, M. V. PY - 2016 DA - 2016// TI - Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies JO - Comput Struct Biotechnol J VL - 14 UR - https://doi.org/10.1016/j.csbj.2016.09.003 DO - 10.1016/j.csbj.2016.09.003 ID - Ruella2016 ER - TY - JOUR AU - Majzner, R. G. AU - Mackall, C. L. PY - 2018 DA - 2018// TI - Tumor antigen escape from CAR T-cell therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0442 DO - 10.1158/2159-8290.CD-18-0442 ID - Majzner2018 ER - TY - JOUR AU - Galon, J. AU - Rossi, J. AU - Turcan, S. PY - 2017 DA - 2017// TI - Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.3025 DO - 10.1200/JCO.2017.35.15_suppl.3025 ID - Galon2017 ER - TY - JOUR AU - John, L. B. AU - Kershaw, M. H. AU - Darcy, P. K. PY - 2013 DA - 2013// TI - Blockade of PD-1 immunosuppression boosts CAR T-cell therapy JO - Oncoimmunology VL - 2 UR - https://doi.org/10.4161/onci.26286 DO - 10.4161/onci.26286 ID - John2013 ER - TY - JOUR AU - Kasakovski, D. AU - Xu, L. AU - Li, Y. PY - 2018 DA - 2018// TI - T cell senescence and CAR-T cell exhaustion in hematological malignancies JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0629-x DO - 10.1186/s13045-018-0629-x ID - Kasakovski2018 ER - TY - JOUR AU - Cherkassky, L. AU - Morello, A. AU - Villena-Vargas, J. PY - 2016 DA - 2016// TI - Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI83092 DO - 10.1172/JCI83092 ID - Cherkassky2016 ER - TY - JOUR AU - Maude, S. L. AU - Hucks, G. E. AU - Seif, A. E. PY - 2017 DA - 2017// TI - The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.103 DO - 10.1200/JCO.2017.35.15_suppl.103 ID - Maude2017 ER - TY - JOUR AU - Ren, J. AU - Liu, X. AU - Fang, C. AU - Jiang, S. AU - June, C. H. AU - Zhao, Y. PY - 2017 DA - 2017// TI - Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1300 DO - 10.1158/1078-0432.CCR-16-1300 ID - Ren2017 ER - TY - JOUR AU - Eyquem, J. AU - Mansilla-Soto, J. AU - Giavridis, T. PY - 2017 DA - 2017// TI - Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection JO - Nature VL - 543 UR - https://doi.org/10.1038/nature21405 DO - 10.1038/nature21405 ID - Eyquem2017 ER - TY - JOUR AU - Qasim, W. AU - Zhan, H. AU - Samarasinghe, S. PY - 2017 DA - 2017// TI - Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells JO - Sci Transl Med VL - 9 UR - https://doi.org/10.1126/scitranslmed.aaj2013 DO - 10.1126/scitranslmed.aaj2013 ID - Qasim2017 ER - TY - JOUR AU - Rupp, L. J. AU - Schumann, K. AU - Roybal, K. T. PY - 2017 DA - 2017// TI - CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-00462-8 DO - 10.1038/s41598-017-00462-8 ID - Rupp2017 ER - TY - JOUR AU - Zhang, Y. AU - Zhang, X. AU - Cheng, C. PY - 2017 DA - 2017// TI - CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells JO - Front Med VL - 11 UR - https://doi.org/10.1007/s11684-017-0543-6 DO - 10.1007/s11684-017-0543-6 ID - Zhang2017 ER - TY - JOUR AU - Jung, I. -. Y. AU - Kim, Y. -. Y. AU - Yu, H. -. S. AU - Kim, S. AU - Thon, J. N. AU - Lee, J. PY - 2017 DA - 2017// TI - CRISPR/Cas9-mediated diacylglycerol kinase knockout potentiates anti-tumor efficacy of human chimeric antigen receptor T-cells JO - Blood VL - 130 ID - Jung2017 ER - TY - JOUR AU - Zhao, J. AU - Lin, Q. AU - Song, Y. AU - Liu, D. PY - 2018 DA - 2018// TI - Universal CARs, universal T cells, and universal CAR T cells JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0677-2 DO - 10.1186/s13045-018-0677-2 ID - Zhao2018 ER - TY - JOUR AU - Chmielewski, M. AU - Kopecky, C. AU - Hombach, A. A. AU - Abken, H. PY - 2011 DA - 2011// TI - IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression JO - Can Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-0103 DO - 10.1158/0008-5472.CAN-11-0103 ID - Chmielewski2011 ER - TY - JOUR AU - Carroll, R. G. AU - Carpenito, C. AU - Shan, X. PY - 2008 DA - 2008// TI - Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells JO - PLoS ONE VL - 3 UR - https://doi.org/10.1371/journal.pone.0003289 DO - 10.1371/journal.pone.0003289 ID - Carroll2008 ER - TY - JOUR AU - Hu, B. AU - Ren, J. AU - Luo, Y. PY - 2017 DA - 2017// TI - Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18 JO - Cell Rep VL - 20 UR - https://doi.org/10.1016/j.celrep.2017.09.002 DO - 10.1016/j.celrep.2017.09.002 ID - Hu2017 ER - TY - JOUR AU - Chmielewski, M. AU - Abken, H. PY - 2017 DA - 2017// TI - CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors JO - Cell Rep. VL - 21 UR - https://doi.org/10.1016/j.celrep.2017.11.063 DO - 10.1016/j.celrep.2017.11.063 ID - Chmielewski2017 ER - TY - JOUR AU - Tanoue, T. AU - Morita, S. AU - Plichta, D. R. PY - 2019 DA - 2019// TI - A defined commensal consortium elicits CD8 T cells and anti-cancer immunity JO - Nature VL - 565 UR - https://doi.org/10.1038/s41586-019-0878-z DO - 10.1038/s41586-019-0878-z ID - Tanoue2019 ER - TY - JOUR AU - Kokai-Kun, J. F. AU - Roberts, T. AU - Coughlin, O. PY - 2017 DA - 2017// TI - The oral beta-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies JO - Antimicrob Agents Chemother VL - 61 UR - https://doi.org/10.1128/AAC.02197-16 DO - 10.1128/AAC.02197-16 ID - Kokai-Kun2017 ER - TY - STD TI - SYN-004 (ribaxamase) protects the gut microbiome of patients treated with ceftriaxone from disruption and reduces the emergence of antimicrobial resistance. Presented at ID week 2018; October 4, 2018; San Francisco, California. Abstract 1337. ID - ref54 ER - TY - STD TI - SYN-006, a novel carbapenemase, intended to protect the gut microbiome from antibiotic-mediated damage may also reduce propagation of carbapenem-resistant pathogens. Presented at ID week 2018; October 4, 2018; San Francisco, California. Abstract 630. ID - ref55 ER - TY - JOUR AU - Alam, S. N. AU - Yammine, H. AU - Moaven, O. PY - 2014 DA - 2014// TI - Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens JO - Ann Surg VL - 259 UR - https://doi.org/10.1097/SLA.0b013e31828fae14 DO - 10.1097/SLA.0b013e31828fae14 ID - Alam2014 ER - TY - JOUR AU - Laurence, M. AU - Hatzis, C. AU - Brash, D. E. PY - 2014 DA - 2014// TI - Common contaminants in next-generation sequencing that hinder discovery of low-abundance microbes JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0097876 DO - 10.1371/journal.pone.0097876 ID - Laurence2014 ER - TY - JOUR AU - Ballester, L. Y. AU - Luthra, R. AU - Kanagal-Shamanna, R. AU - Singh, R. R. PY - 2016 DA - 2016// TI - Advances in clinical next-generation sequencing: target enrichment and sequencing technologies JO - Expert Rev Mol Diagn VL - 16 UR - https://doi.org/10.1586/14737159.2016.1133298 DO - 10.1586/14737159.2016.1133298 ID - Ballester2016 ER - TY - JOUR AU - Kim, D. AU - Hofstaedter, C. E. AU - Zhao, C. PY - 2017 DA - 2017// TI - Optimizing methods and dodging pitfalls in microbiome research JO - Microbiome VL - 5 UR - https://doi.org/10.1186/s40168-017-0267-5 DO - 10.1186/s40168-017-0267-5 ID - Kim2017 ER - TY - JOUR AU - Goodrich, J. K. AU - Rienzi, S. C. AU - Poole, A. C. PY - 2014 DA - 2014// TI - Conducting a microbiome study JO - Cell VL - 158 UR - https://doi.org/10.1016/j.cell.2014.06.037 DO - 10.1016/j.cell.2014.06.037 ID - Goodrich2014 ER - TY - JOUR AU - Smith, M. AU - Littmann, E. AU - Slingerland, J. PY - 2019 DA - 2019// TI - Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy JO - Biol Blood Marrow Transplant VL - 25 UR - https://doi.org/10.1016/j.bbmt.2018.12.319 DO - 10.1016/j.bbmt.2018.12.319 ID - Smith2019 ER - TY - JOUR AU - Abid, M. B. AU - Koh, C. J. PY - 2019 DA - 2019// TI - Probiotics in health and disease: fooling mother nature? JO - Infection UR - https://doi.org/10.1007/s15010-019-01351-0 DO - 10.1007/s15010-019-01351-0 ID - Abid2019 ER -